Review
Immunology
Yao-Ning Feng, Guang-Yu Xie, Li Xiao, Dun-Chang Mo, Jian-Feng Huang, Peng-Hui Luo, Xiu-Juan Liang
Summary: A systematic review and analysis of randomized controlled trials (RCTs) on immune checkpoint inhibitor (ICI) combination therapy for metastatic renal cell carcinoma (mRCC) found that compared to conventional tyrosine kinase inhibitor (TKI)-targeted therapy, ICI combination therapy has less hematotoxicity but more specific hepatotoxicity, gastrointestinal toxicity, endocrine toxicity, and nephrotoxicity in mRCC patients, with a similar profile of severe toxicity.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Steven Nicolaides, Alex Boussioutas
Summary: Immunotherapy is an effective cancer treatment that activates the immune system to target and destroy cancer cells. However, the use of immune checkpoint inhibitors is often limited by immune-related adverse events. This review focuses on the management and emerging therapies for immune-related adverse events in the gastrointestinal system.
Review
Gastroenterology & Hepatology
Byung Min Lee, Jinsil Seong
Summary: ICIs have shown clinical efficacy against most solid cancers, and recent success in combination therapy with targeted agents in hepatocellular carcinoma has accelerated the search for novel combination strategies. Additionally, radiotherapy can be combined with ICIs to modulate the tumor immune microenvironment.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Immunology
Linyang Gan, Huan Chen, Xiaowei Liu, Li Zhang
Summary: This study investigated the incidence of immune-related adverse events (irAEs) of immune checkpoint inhibitor therapy and reported the clinical features, management, and outcomes of ophthalmic irAEs. Medical records of 962 patients who received ICI therapy were retrospectively reviewed, and 248 patients (25.8%) experienced irAEs. The first-year incidences of total irAEs and ophthalmic irAEs were 23.5% and 1.1% respectively. The most common ICI received was pembrolizumab (38.8%).
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Kavita M. Dhodapkar, Alyssa Duffy, Madhav V. Dhodapkar
Summary: Blocking immune checkpoints has revolutionized cancer therapy, but immune-related adverse events (irAEs) pose a challenge to its clinical application. B cells, known players in autoimmunity, have been targeted successfully for autoimmune disorders. While T cells have been extensively studied in immune checkpoint blockade (ICB), these checkpoints also affect B cell tolerance. This review focuses on the role of humoral immunity, specifically B cell subsets and autoantibodies, in the pathogenesis of ICB-induced irAEs. Understanding T:B cell cross talk may uncover new targets or strategies to prevent or treat irAEs and improve ICB therapy in cancer.
IMMUNOLOGICAL REVIEWS
(2023)
Article
Endocrinology & Metabolism
Christopher A. Muir, Roderick J. Clifton-Bligh, Georgina Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang, Alexander M. Menzies
Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with different subtypes of thyroid immune-related adverse events having unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer progression free survival and overall survival, while hypothyroidism showed no association with cancer outcomes. Multiple distinct phenotypes of thyroid irAEs suggest potentially different etiologies for thyrotoxicosis and hypothyroidism.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Christopher A. Muir, Roderick J. Clifton-Bligh, Georgina V. Long, Richard A. Scolyer, Serigne N. Lo, Matteo S. Carlino, Venessa H. M. Tsang, Alexander M. Menzies
Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with distinct phenotypes of thyroid irAEs showing unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer survival outcomes, while no association was found between hypothyroidism and cancer outcomes.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Biochemistry & Molecular Biology
Quang Minh Dang, Ryu Watanabe, Mayu Shiomi, Kazuo Fukumoto, Tomomi W. Nobashi, Tadashi Okano, Shinsuke Yamada, Motomu Hashimoto
Summary: With the increase in elderly patients, malignancies are becoming more common in rheumatoid arthritis (RA) patients and often pose challenges to RA treatment. Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment option for various malignancies by blocking immunological brakes on T lymphocytes. However, ICIs are also associated with numerous immune-related adverse events (irAEs) including hypophysitis, myocarditis, pneumonitis, and colitis. Moreover, ICIs can exacerbate existing autoimmune diseases and cause rheumatic irAEs such as arthritis, myositis, and vasculitis. This review provides a comprehensive summary of the mechanisms, management, and potential therapeutic strategies for rheumatic irAEs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Endocrinology & Metabolism
Christopher A. Muir, Venessa H. M. Tsang, Alexander M. Menzies, Roderick J. Clifton-Bligh
Summary: The translated article introduces immune checkpoints, immune checkpoint inhibitors, and the association of thyroid dysfunction with immune-related adverse events (irAEs). Thyroid irAEs may be associated with increased immune toxicity in other organ systems and longer progression-free and overall survival.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Takashi Ikeda, Hiroki Ishihara, Yuki Nemoto, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Toshio Takagi, Junpei Iizuka, Yasunobu Hashimoto, Hideki Ishida, Tsunenori Kondo, Kazunari Tanabe
Summary: In patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab, the development of immune-related adverse events (irAEs) was significantly associated with progression-free survival (PFS) but not with overall survival (OS). irAE development may be used as a surrogate prognostic marker for PFS in this treatment regimen.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Kathleen M. Capaccione, Jacienta P. Valiplackal, Alice Huang, Tina Roa, Alana Fruauff, Connie Liou, Eleanor Kim, Sakshi Khurana, Mary Maher, Hong Ma, Pamela Ngyuen, Serena Mak, Shifali Dumeer, Sonali Lala, Belinda D'souza, Sherelle Laifer-Narin, Elise Desperito, Carrie Ruzal-Shapiro, Mary M. Salvatore
Summary: Cancer immunotherapies modulate the body's immune system to enhance immune response against cancer. However, immune-related adverse events (IRAEs) can result from these therapies, making it crucial for radiologists to recognize and manage them effectively.
ACADEMIC RADIOLOGY
(2022)
Article
Oncology
Bettzy Stephen, Joud Hajjar, Shrutii Sarda, Dzifa Yawa Duose, Jeffrey M. Conroy, Carl Morrison, Anas Alshawa, Mingxuan Xu, Abdulrazzak Zarifa, Sapna P. Patel, Ying Yuan, Evan Kwiatkowski, Linghua Wang, Jordi Rodon Ahnert, Siqing Fu, Funda Meric-Bernstam, Geoffrey M. Lowman, Timothy Looney, Aung Naing
Summary: Immune checkpoint inhibitors have greatly improved cancer treatment but also come with immune-related adverse events (irAEs). Evaluating the link between polymorphisms in the TRBV gene and irAEs could help find predictive biomarkers. Long-amplicon TCRB sequencing may identify TRBV haplotypes associated with the risk of severe irAEs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Anesthesiology
Adrienne K. Ho, Anthony M-H Ho, Tim Cooksley, Giang Nguyen, Jason Erb, Glenio B. Mizubuti
Summary: Immune checkpoint inhibitors are a new treatment modality for cancer that can restore antitumor immunity by blocking the binding of cancer cell proteins to T-cell checkpoints. However, they may also lead to immune-related adverse events, including autoimmune complications.
ANESTHESIA AND ANALGESIA
(2021)
Article
Immunology
Li Zeng, Gang Ma, Kai Chen, Qiao Zhou
Summary: This study examined the trend of ICIs-associated rheumatic irAEs using bibliometric methods, finding that the United States is the leading contributor and observing shifts in research focus through keyword analysis and citation bursts.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Kristian C. Williams, Abigail Gault, Amy E. Anderson, Christopher J. Stewart, Christopher A. Lamb, R. Ally Speight, Neil Rajan, Ruth Plummer, Arthur G. Pratt
Summary: Checkpoint inhibitors (CPIs) disrupt immune checkpoint molecules to block regulatory immune signals, but can cause immune-related adverse events (irAEs) similar to autoimmune diseases. Understanding irAE pathobiology may lead to targeted mitigation strategies and predictive biomarkers. This review focuses on irAEs in the gut, skin, and synovial joints, comparing them to immune-mediated diseases. Studies show dysregulation of cytokines, T-cell infiltration, and potential therapeutic opportunities for irAEs.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Tatsuya Konishi, Noritaka Sekiya, Yuki Otsuka, Ryosuke Konuma, Atsushi Wada, Hiroto Adachi, Yuya Kishida, Akihito Nagata, Yuta Yamada, Yuma Noguchi, Atsushi Marumo, Junichi Mukae, Kyoko Inamoto, Takashi Toya, Aiko Igarashi, Yuho Najima, Takeshi Kobayashi, Hisashi Sakamaki, Kazuteru Ohashi, Noriko Doki
Summary: Allogeneic hematopoietic stem cell transplantation recipients are at high risk of developing invasive pneumococcal disease, with vaccination being crucial for prevention. While treatment can lead to good short-term outcomes, the majority of IPD cases occur in unvaccinated patients.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Shunichiro Yasuda, Yuho Najima, Tatsuya Konishi, Yuta Yamada, Akihito Nagata, Toshiaki Takezaki, Satoshi Kaito, Shuhei Kurosawa, Masahiro Sakaguchi, Kaito Harada, Naoki Shingai, Kosuke Yoshioka, Kyoko Inamoto, Junichi Mukae, Takashi Toya, Aiko Igarashi, Hiroaki Shimizu, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Norihiko Kawamata, Kazuteru Ohashi, Noriko Doki
Summary: The outcomes of allo-HSCT for T-ALL/LBL were comparable to those of Ph-negative B-ALL, and achieving complete remission before allo-HSCT was associated with a favorable overall survival for patients, regardless of disease subtypes. Further advancements in chemotherapy and determining the optimal timing of allo-HSCT could improve the prognosis of patients with T-ALL/LBL.
Letter
Hematology
Yuta Yamada, Tatsuya Konishi, Akihito Nagata, Takashi Toya, Yuho Najima, Takeshi Kobayashi, Kazuteru Ohashi, Noriko Doki
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Yuta Yamada, Shuntaro Ikegawa, Yuho Najima, Yuya Atsuta, Ryosuke Konuma, Hiroto Adachi, Atsushi Wada, Yuya Kishida, Tatsuya Konishi, Akihito Nagata, Satoshi Kaito, Ryohei Nagata, Yuma Noguchi, Atsushi Marumo, Junichi Mukae, Kyoko Inamoto, Takashi Toya, Aiko Igarashi, Takeshi Kobayashi, Hisashi Sakamaki, Kazuteru Ohashi, Noriko Doki
Summary: The study found that reducing melphalan dose did not significantly impact transplant outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation, except for those with high-risk diseases. Different reduced-intensity conditioning regimens showed comparable results in terms of overall survival, relapse rate, and non-relapse mortality.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2022)
Meeting Abstract
Oncology
Ryuta Watanabe, Masashi Maekawa, Takeshi Kiyoi, Mie Kurata, Noriyoshi Miura, Tadahiko Kikugawa, Shigeki Higashiyama, Takashi Saika
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Atsushi Marumo, Ikuko Omori, Shuhei Tara, Yuki Otsuka, Ryosuke Konuma, Hiroto Adachi, Atsushi Wada, Yuya Kishida, Tatsuya Konishi, Akihito Nagata, Yuta Yamada, Ryohei Nagata, Yuma Noguchi, Takashi Toya, Aiko Igarashi, Yuho Najima, Takeshi Kobayashi, Hiroki Yamaguchi, Koiti Inokuchi, Hisashi Sakamaki, Kazuteru Ohashi, Noriko Doki
Summary: Cyclophosphamide (CY)-induced cardiotoxicity is rare but potentially lethal. Lowering the dose of CY can reduce the risk of heart failure, but even doses below 120 mg/kg can still cause cardiotoxicity.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Infectious Diseases
Shuichi Shirane, Yuho Najima, Kazuaki Fukushima, Noritaka Sekiya, Nobuaki Funata, Yuya Kishida, Akihito Nagata, Yuta Yamada, Tatsuya Konishi, Satoshi Kaito, Shuhei Kurosawa, Kota Yoshifuji, Tomoyuki Uchida, Kyoko Inamoto, Naoki Shingai, Takashi Toya, Aiko Igarashi, Hiroaki Shimizu, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi, Shin-ichiro Horiguchi, Tsunekazu Hishima, Noriko Doki
Summary: This case study presents a patient with a brain abscess caused by mucormycosis, diagnosed using burr craniotomy. The patient underwent cord blood transplantation and died from hemorrhagic cystitis and aspiration pneumonia. Prompt initiation of antifungal therapy and debridement are crucial for the prognosis of cerebral mucormycosis.
JOURNAL OF INFECTION AND CHEMOTHERAPY
(2022)
Article
Oncology
Hiroaki Ogawa, Tatsuya Konishi, Yuho Najima, Satoshi Kito, Shimpei Hashimoto, Chika Kato, Satoshi Sakai, Yasuhiro Kanbara, Yuya Atsuta, Ryosuke Konuma, Atsushi Wada, Daisuke Murakami, Shiori Nakasima, Yusuke Uchibori, Daishi Onai, Atsushi Hamamura, Akihiko Nishijima, Naoki Shingai, Takashi Toya, Hiroaki Shimizu, Takeshi Kobayashi, Kazuteru Ohashi, Noriko Doki, Keiko Nemoto Murofushi
Summary: This study aimed to determine the recommended dose of 3-day total marrow and lymphoid irradiation (TMLI) for myeloablative conditioning regimen and evaluate its safety and efficacy. The recommended dose was found to be 6 fractions of 18 Gy. Patients had high survival rates one year post-transplantation, but some experienced relapse.
Article
Biochemistry & Molecular Biology
Ryuta Watanabe, Noriyoshi Miura, Mie Kurata, Riko Kitazawa, Tadahiko Kikugawa, Takashi Saika
Summary: This report describes a case of a 78-year-old man with concurrent de novo NEPC and ARPC. Spatial gene expression analysis revealed upregulation of neuroendocrine signatures in the NEPC sites and upregulation of androgen receptor signatures in the ARPC sites. TP53, RB1, or PTEN were not downregulated in the NEPC sites, and homologous recombination repair genes were upregulated. The accumulation of cases and basic data will contribute to the development of novel treatments for NEPC and improvement of prognosis in patients with castration-resistant prostate cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Hematology
Tatsuya Konishi, Toshiki Ochi, Masaki Maruta, Kazushi Tanimoto, Yukihiro Miyazaki, Chika Iwamoto, Takashi Saitou, Takeshi Imamura, Masaki Yasukawa, Katsuto Takenaka
Summary: The development of a bridging-BiTE (B-BiTE) method enhances the efficacy of immunotherapy for multiple myeloma. By binding with clinically available monoclonal antibodies (mAbs), the B-BiTE modality successfully induces antitumor T-cell responses and enhances antimyeloma effects. Sequential immunotherapy using different mAb/B-BiTE complexes further augments immune responses to myeloma and circumvents myeloma cell antigen escape.
Meeting Abstract
Urology & Nephrology
Kenichi Nishimura, Reina Kouno, Ryuta Watanabe, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yuki Miyauchi, Tadahiko Kikugawa, Takashi Saika
INTERNATIONAL JOURNAL OF UROLOGY
(2022)